MainReads
← Details
Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan.
Tamura K, Tsujino T, Taoka R, Kobayashi K, Miyake M, Ogawa K, Sasaki Y, Tatarano S, Katayama S, Kato M, Fukuhara H, Abe Y, Oda Y, Minato R, Shigehisa R, Maenosono R, Sugimoto M, Shiraishi K, Fujimoto K, Wada K, Furukawa J, Enokida H, Araki M, Uchida J, Inoue K, Inamoto T, West Japan Uro-oncology Collaboration Group
/
-
Loading document from repository...
Unable to Display Document
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.